{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:25:12Z","timestamp":1780500312786,"version":"3.54.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01533-8","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:53:16Z","timestamp":1780498396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival trends in the era of novel therapies identify unmet needs in peripheral T-cell lymphoma: a national cancer database analysis"],"prefix":"10.1038","volume":"16","author":[{"given":"Julia","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8358-5953","authenticated-orcid":false,"given":"N. Nora","family":"Bennani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Kyoung","family":"Tiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5645-0949","authenticated-orcid":false,"given":"Arushi","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1860-2424","authenticated-orcid":false,"given":"Urshila","family":"Durani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-5531","authenticated-orcid":false,"given":"Jonas","family":"Paludo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gita","family":"Thanarajasingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6536-1291","authenticated-orcid":false,"given":"Steven R.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6955-9393","authenticated-orcid":false,"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3532-9132","authenticated-orcid":false,"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1244-6758","authenticated-orcid":false,"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3939-6252","authenticated-orcid":false,"given":"Jithma P.","family":"Abeykoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"1533_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo I, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348.","journal-title":"Leukemia"},{"key":"1533_CR2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229\u201353.","journal-title":"Blood"},{"key":"1533_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","volume":"20","author":"SM Horwitz","year":"2022","unstructured":"Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Choi M, et al. T-cell lymphomas, version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:285\u2013308.","journal-title":"J Natl Compr Canc Netw"},{"key":"1533_CR4","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1182\/blood.2023020912","volume":"144","author":"L Shea","year":"2024","unstructured":"Shea L, Mehta-Shah N. Peripheral T-cell lymphoma: are all patients high risk? Blood. 2024;144:2604\u201312.","journal-title":"Blood"},{"key":"1533_CR5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","volume":"33","author":"S Horwitz","year":"2022","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. The ECHELON-2 trial: 5-year results of a randomized phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33:288\u201398.","journal-title":"Ann Oncol"},{"key":"1533_CR6","doi-asserted-by":"crossref","unstructured":"Ruan J, Chen Z, Larson MC, Bennani NN, Allen PB, Mou E, et al. Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study. Blood Adv. 2026;10:3480\u201393.","DOI":"10.1182\/bloodadvances.2025018455"},{"key":"1533_CR7","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1182\/blood.2023021789","volume":"144","author":"AJ Moskowitz","year":"2024","unstructured":"Moskowitz AJ, Stuver RN, Horwitz SM. Current and upcoming treatment approaches to common subtypes of peripheral T-cell lymphoma (PTCL-NOS, ALCL, and TFH lymphomas). Blood. 2024;144:1887\u201397.","journal-title":"Blood"},{"key":"1533_CR8","doi-asserted-by":"publisher","first-page":"S860","DOI":"10.1016\/S2152-2650(25)02489-9","volume":"25","author":"LC Pinter-Brown","year":"2025","unstructured":"Pinter-Brown LC, Mehta-Shah N, Zinzani PL, Jacobsen ED, Zain J, Mead M, et al. Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma: final results from the phase 2 PRIMO trial. Clin Lymphoma Myeloma Leuk. 2025;25:S860\u2013S861.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1533_CR9","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1182\/bloodadvances.2024012806","volume":"8","author":"T Witzig","year":"2024","unstructured":"Witzig T, Sokol L, Kim WS, de la Cruz Vicente F, Mart\u00edn Garc\u00eda-Sancho A, Advani R, et al. Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed\/refractory peripheral T-cell lymphoma. Blood Adv. 2024;8:4581\u201392.","journal-title":"Blood Adv"},{"key":"1533_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fonc.2019.00259","volume":"9","author":"I Scarf\u00f2","year":"2019","unstructured":"Scarf\u00f2 I, Frigault MJ, Maus MV. CAR-based approaches to cutaneous T-cell lymphoma. Front Oncol. 2019;9:259.","journal-title":"Front Oncol"},{"key":"1533_CR11","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/bjh.14477","volume":"176","author":"D Chihara","year":"2017","unstructured":"Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, et al. Survival outcomes of patients with relapsed or refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017;176:750\u20138.","journal-title":"Br J Haematol"},{"key":"1533_CR12","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Tr\u00fcmper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116:3418\u201325.","journal-title":"Blood"},{"key":"1533_CR13","first-page":"101160","volume":"50","author":"MC Cai","year":"2024","unstructured":"Cai MC, Zhang W, Li ZM, Li X, Liu WP, Song YQ, et al. Targeted agents plus CHOP versus CHOP as first-line treatment for newly diagnosed peripheral T-cell lymphoma (GUIDANCE-03): an open-label multicentre phase II trial. Lancet Reg Health West Pac. 2024;50:101160.","journal-title":"Lancet Reg Health West Pac"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01533-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01533-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01533-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:53:18Z","timestamp":1780498398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01533-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1533"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01533-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NNB has received honoraria as a consultant and advisory board member for Acrotech Biopharma and for serving on the Scientific Review Committee for Pfizer. YKT has received honoraria as a consultant for Acrotech, Novartis, Kite, MJH Life Sciences, and Plexus Communications. JP has received research funding from Karyopharm, Biofourmis, and AstraZeneca, and honoraria from AbbVie, all paid to his institution. YW has received research funding to his institution from Incyte, InnoCare, LOXO Oncology, Eli Lilly, MorphoSys, Novartis, Genentech, Genmab, AbbVie, BeiGene, Merck, AstraZeneca, and Bristol Myers Squibb; advisory board compensation to his institution from Eli Lilly, LOXO Oncology, TG Therapeutics, Incyte, InnoCare, Kite, Jansen, BeiGene, AstraZeneca, Genmab, and AbbVie; consultancy compensation to his institution from InnoCare and AbbVie; and honoraria to his institution from Kite. TMH has received honoraria for serving on Data Monitoring Committees for Seagen and Eli Lilly & Co, and research support for the LEO grant from Genentech, Bristol Myers Squibb, and Genmab, as well as additional research support from Sorrento; all payments were made to his institution. SMA has received research funding for clinical trials from Bristol Myers Squibb, Takeda, Pfizer, Regeneron, AstraZeneca, Affimed, StepPharma, and ADC Therapeutics. JPA has received research funding from Qurion, CRISPR Therapeutics, Eli Lilly and BioMed Valley Discoveries for clinical trials, all paid to his institution.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}